Twenty years of peer-reviewed kisspeptin trials, distilled

The short version

Kisspeptin is a peptide your body makes that sits at the top of the reproductive hormone chain. When it fires, it triggers a cascade — GnRH release, then LH and FSH from the pituitary, then sex-steroid output from the gonads. The Imperial College London Dhillo group has been studying it in registered clinical trials since 2005 across six areas: restoring hormone cycles in women who have lost their periods, triggering egg maturation in IVF without the usual complication risk, sexual desire processing in the brain, bone metabolism, liver metabolism, and a non-invasive nasal-spray delivery route demonstrated in 2025. Kisspeptin is not approved by any regulator for any use. All the human data on this site comes from those supervised research trials. For what research participants and the broader research-use community say they notice — beyond the published outcomes — see the effects page.

What is kisspeptin?

Kisspeptin is a family of peptides produced from the KISS1 gene — a single gene on chromosome 1 encoding a 145-amino-acid precursor that is proteolytically cleaved into multiple active isoforms. The two most studied are kisspeptin-10 (KP-10), a 10-amino-acid C-terminal decapeptide, and kisspeptin-54 (KP-54), the predominant form in human circulation. Both share the same C-terminal RF-amide sequence — the structural motif required for binding to KISS1R (GPR54), the G-protein-coupled receptor through which kisspeptin exerts its effects ^[10].

The compound was originally identified as a tumor metastasis suppressor — the gene was named KISS1 after Hershey, Pennsylvania, the home of Hershey's Kisses — before its central role in reproductive neuroendocrinology was established. Loss-of-function mutations in KISS1R cause idiopathic hypogonadotropic hypogonadism, a condition in which puberty fails to occur; gain-of-function mutations in the same receptor cause central precocious puberty ^[10]. These human genetic findings established that kisspeptin signaling is not merely modulatory but is the primary gate for human reproductive axis activation.

Molecular weights differ substantially between isoforms: kisspeptin-10 is 1,302.5 Da; kisspeptin-54 is approximately 6,264 Da. This size difference affects plasma half-life — kisspeptin-10 clears in approximately 4 minutes after intravenous administration, while kisspeptin-54 has a plasma half-life of approximately 27–28 minutes ^[3].

Kisspeptin is not approved by the FDA, EMA, or any major regulatory agency for any therapeutic indication as of 2025. All human data reviewed on this site derives from registered clinical trials conducted under ethical oversight at academic medical centers.

How kisspeptin works

Kisspeptin binds KISS1R, triggering a Gq/11-coupled signaling cascade: phospholipase C activation leads to IP3/DAG production, intracellular calcium mobilization, and MAPK/ERK1/2 phosphorylation. In the hypothalamus, this cascade depolarizes GnRH neurons, causing pulsatile GnRH release into the portal circulation. Pituitary gonadotrophs respond with LH and FSH secretion, which drives gonadal steroidogenesis — the production of testosterone, estradiol, and progesterone ^[9].

The anatomical architecture of kisspeptin's action is now well-characterized. Two distinct populations of kisspeptin neurons serve different functions. Neurons in the arcuate nucleus (ARC) co-express neurokinin B (stimulatory) and dynorphin A (inhibitory), forming what is called the KNDy circuit — the mammalian GnRH pulse generator. NKB initiates each synchronized pulse, dynorphin terminates it, and kisspeptin is the output signal to GnRH neurons ^[9]. A separate population in the anteroventral periventricular nucleus (AVPV) mediates the positive estradiol-feedback LH surge that triggers ovulation ^[17].

The first demonstration that kisspeptin activates the human reproductive axis was published in 2005 by Dhillo et al., who showed that intravenous kisspeptin-54 infusion at 0.25–12 pmol/kg/min produced a dose-dependent increase in serum LH in healthy adult men — the first proof-of-concept for kisspeptin as a driver of gonadotropin secretion in humans ^[1].

What the trial record shows

The 20 years of Imperial College kisspeptin research covers six principal areas of investigation: reproductive hormone restoration, IVF oocyte triggering, hypoactive sexual desire disorder, bone metabolism, metabolic liver disease, and intranasal delivery formulation.

In women with hypothalamic amenorrhea — a condition of reproductive axis suppression caused by stress, energy deficit, or both — continuous intravenous kisspeptin-54 infusion temporarily restored pulsatile LH secretion. At optimal intermediate doses, LH pulse number increased 3-fold and pulse secretory mass increased 6-fold versus vehicle ^[2]. In IVF protocols where conventional hCG triggering carries risk of ovarian hyperstimulation syndrome (OHSS), a single subcutaneous kisspeptin-54 bolus at 12.8 nmol/kg triggered oocyte maturation in 95% of high-OHSS-risk patients, with 0% moderate, severe, or critical OHSS and a 45% live birth rate per transfer ^[4].

For hypoactive sexual desire disorder, a double-blind randomized trial in men demonstrated that IV kisspeptin-54 infusion (1 nmol/kg/h, 75 minutes) significantly altered brain activity in sexual-processing networks (Cohen d=0.81, p=0.003) and increased penile tumescence up to 56% more than placebo ^[6]. A parallel trial in premenopausal women with low sexual desire found altered fMRI activation in the inferior frontal gyrus, postcentral gyrus, and temporoparietal junction, with hippocampal enhancement correlating with reduced sexual distress ^[7].

A 2022 study measured bone formation markers after acute kisspeptin IV infusion in 26 healthy men: total osteocalcin rose 20.3% and carboxylated osteocalcin rose 24.3% at peak; in vitro human osteoblast alkaline phosphatase increased 41% and osteoclast resorptive activity decreased by up to 53% ^[8].

In 2025, the Imperial College group, in collaboration with INSERM, published the first demonstration that intranasal kisspeptin delivery robustly stimulates gonadotropin release in humans. At 12.8 nmol/kg intranasal, mean LH increased 4.4 ± 0.6 IU/L (p=0.002 versus placebo) in healthy men, with effects also demonstrated in women and hypothalamic amenorrhea patients [cited in research section]. The formulation remained stable for 60 days at 4°C.

Scope of this site

Kisspeptin Reviews is an independent editorial project that summarizes the peer-reviewed research literature on kisspeptin. Every quantitative claim on this site is sourced to a registered clinical trial, a peer-reviewed journal article, or a published systematic review. No claim is sourced to anecdotal reports, bodybuilding forums, or commercial vendor literature.

The site organizes the evidence into four primary reading paths: the mechanism page covers KISS1R signaling and KNDy circuit architecture; the research page reviews individual trial findings with inline citations; the dosage page documents the administration parameters studied in registered protocols; the FAQ addresses the most common questions about the compound's biology and investigational status. The references page provides the full citation list with DOIs and PubMed identifiers for independent verification.

This site is an independent editorial commentary on publicly available science. It is not affiliated with any vendor, clinic, or commercial entity.